City Therapeutics prices upsized $200m IPO on Nasdaq
City Therapeutics has priced its upsized initial public offering at $18.00 per share, raising approximately $200 million in gross proceeds before underwriting costs and fees. The Cambridge, Massachusetts company offered 11,111,111 shares and is expected to begin trading on the Nasdaq Global Market under the ticker "CTY" on 16 October 2026, with the offering set to close on 19 October, subject to customary conditions.
The deal was upsized from its original terms, a signal of robust demand from institutional investors. Underwriters have also been granted a 30-day option to purchase up to an additional 1,666,666 shares at the IPO price, which could lift total gross proceeds to approximately $230 million if exercised in full. Goldman Sachs, Jefferies, Stifel and Oppenheimer are acting as joint book-running managers.
The pipeline
City is a clinical-stage company building what it describes as a next-generation RNAi platform. Its three lead programmes span distinct therapeutic areas: CITY-FXI targets thromboembolic diseases by silencing coagulation Factor XI; CITY-RBP4 is aimed at Stargardt disease and other retinal conditions driven by excess retinol-binding protein 4; and CITY-TFR2 addresses anaemia associated with chronic diseases by modulating transferrin receptor 2. The company's proprietary "cityRNA" trigger chemistry is positioned as an advance on conventional RNAi constructs, and the platform incorporates tissue-selective delivery and genetics-driven target selection.
No clinical data, trial phase updates or efficacy readouts were included in the IPO pricing announcement. Investors will need to consult the full prospectus, now effective with the SEC, for trial timelines, preclinical and clinical results, and cash runway projections.
Market context
City's float arrives into a biotech IPO market that has been recovering steadily through 2025 and 2026 after a prolonged drought. A handful of clinical-stage companies have successfully priced above the $150 million threshold this year, and the demand to upsize City's deal suggests investors remain willing to back platform-stage RNA therapeutics with diversified pipelines.
The RNAi sector has grown considerably more competitive since Alnylam Pharmaceuticals demonstrated the commercial viability of the modality with Onpattro and, more recently, with inclisiran's cardiovascular indication. A number of well-capitalised companies, including Arrowhead Pharmaceuticals and Silence Therapeutics, are advancing their own next-generation RNAi constructs with proprietary chemistries and delivery systems. City's differentiation thesis rests on its cityRNA trigger engineering and multi-tissue delivery capability, though this will require clinical validation to stand up against more established platforms.
The Factor XI anticoagulation space is particularly active, with several programmes in late-stage development from larger pharmaceutical groups. City's ability to carve out a competitive position there will be closely watched alongside its retinal and anaemia programmes as the company transitions from private to public scrutiny.